Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 8,146 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

NCT06247488
View directory record Official record
Conditions
Abuse Potential
Interventions
Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers

NCT01074710
View directory record Official record
Conditions
Gastroparesis
Interventions
[2-13C] uracil, [2-13C] uracil, placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2010 · Synced Oct 24, 2026, 2:49 PM EDT
Completed No phase listed Observational

Evaluation of a New Oral Contrast Agent for MR Enterography in the Assessment of Crohn Disease in the Small Bowel

NCT00587210
View directory record Official record
Conditions
Crohn Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

NCT02531113
View directory record Official record
Conditions
Crohn's Disease
Interventions
RPC1063
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 24, 2026, 2:49 PM EDT
Withdrawn No phase listed Observational

Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant

NCT02589860
View directory record Official record
Conditions
Mucositis, Multiple Myeloma, Amyloidosis, Oral Mucositis
Interventions
Melphalan kinetic study, Oral bacterial study, Gene expression study
Other · Genetic
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Not applicable Interventional Results available

Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity

NCT02113579
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Experimental Mouth Rinse 12027-033, Placebo Mouth Rinse
Device · Other
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Fort Wayne, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 24, 2026, 2:49 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

NCT02935673
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Fresno, California • Orange, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

NCT04391894
View directory record Official record
Conditions
Dry Eye
Interventions
ECF843, ECF843 vehicle
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Results available

A Phase I Study to Evaluate the Oral Absorption of Nepadutant in Infants

NCT00655083
View directory record Official record
Conditions
Infantile Colic, Infantile Functional Gastrointestinal Disorders
Interventions
Nepadutant
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
6 Weeks to 24 Weeks
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Little Rock, Arkansas • Louisville, Kentucky • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2011 · Synced Oct 24, 2026, 2:49 PM EDT
Not listed Not applicable Interventional

Preterm Functional Early Enteral Development (FEED) Trial on Respiratory Support

NCT04531566
View directory record Official record
Conditions
Premature Birth
Interventions
Oral Feed, Usual care
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
32 Weeks and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

NCT03561883
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
IW-3718, placebo, Standard-dose PPIs QD
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
98
States / cities
Birmingham, Alabama • Dothan, Alabama • Peoria, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)

NCT06450366
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Enlicitide, Ezetimibe, Bempedoic Acid, Placebo for Enlicitide, Placebo for Ezetimibe, Placebo for Bempedoic Acid
Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Lincoln, California • Flossmoor, Illinois • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 2 Interventional Results available

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186
View directory record Official record
Conditions
Early-stage Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 24, 2026, 2:49 PM EDT
Completed No phase listed Observational

VCRC Patient Contact Registry Patient-Reported Data Validation Study

NCT02190942
View directory record Official record
Conditions
Behcet's Disease, Churg-Strauss Syndrome, Giant Cell Arteritis, Wegener Granulomatosis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
Not listed
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 24, 2026, 2:49 PM EDT
Terminated Phase 2 Interventional Results available

Study of the Oral Treatment MTR-601 in Cervical Dystonia

NCT06830642
View directory record Official record
Conditions
Cervical Dystonia
Interventions
MTR-601, Placebo
Drug
Lead sponsor
Motric Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimization of Pre-operative Oral Analgesics in Patients Undergoing Ambulatory Minimally Invasive Hysterectomy

NCT03420794
View directory record Official record
Conditions
Hysterectomy, Laparoscopy, Analgesia
Interventions
Timing of pre-operative oral non-narcotic analgesics in relation to minimally invasive hysterectomy
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Dis/Reconnection of Implant Abutments on Peri-implant Bone Levels

NCT04043286
View directory record Official record
Conditions
Bone Loss, Implant Complication, Gingival Recession
Interventions
Definitive abutment
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

NCT00371670
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
balicatib (AAE581)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
223 participants
Timeline
Started 2004
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 24, 2026, 2:49 PM EDT
Active, not recruiting Phase 3 Interventional

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
View directory record Official record
Conditions
Arteriosclerosis, Hypercholesterolaemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
14,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
132
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

NCT02922127
View directory record Official record
Conditions
Contraception
Interventions
Ulipristal Acetate, Combined Oral Contraceptive Pill
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Botswana TDF/FTC Oral HIV Prophylaxis Trial

NCT00448669
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg, Placebo Oral Tablet
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 39 Years
Enrollment
1,219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

NCT05093205
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NPC-12G Gel 0.2% Sirolimus PK Bridging Study

NCT03972462
View directory record Official record
Conditions
Bioavailability Study
Interventions
NPC-12G Gel 0.2%, Rapamune® 2 mg tablet
Drug
Lead sponsor
Nobelpharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 24, 2026, 2:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

NCT04529538
View directory record Official record
Conditions
Poliomyelitis
Interventions
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 24, 2026, 2:49 PM EDT